Travere Therapeutics (NASDAQ:TVTX), formerly known as Retrophin, is a biopharmaceutical company focused on developing and commercializing therapies for rare kidney and rare metabolic diseases. Headquartered in San Diego, California, Travere concentrates on addressing significant unmet medical needs in conditions such as cystinosis, IgA nephropathy, and lipoprotein lipase deficiency. The company’s mission is to improve patient outcomes through targeted therapies that slow disease progression and alleviate debilitating symptoms.
Among its marketed products, Travere offers PROCYSBI® (cysteamine bitartrate) delayed‐release capsules for the treatment of nephropathic cystinosis, a rare genetic disorder characterized by the accumulation of cystine in various organs. Other approved therapies include CHENODAL® (chenodiol) tablets for the dissolution of gallstones in patients who cannot undergo surgery, and KYSTEXXA® (pegloticase) for patients with refractory chronic gout. Travere continues to expand its portfolio through clinical trials and regulatory filings, including investigations into treatments for kidney fibrosis and other progressive renal diseases.
Since its founding in 2013, Travere has built a leadership team with deep expertise in nephrology and rare disease development. The company’s executive team is led by Chief Executive Officer John H. Johnson, who brings over 25 years of experience in biotechnology and healthcare. The organization emphasizes collaboration with patient advocacy groups and medical experts to guide its research priorities and ensure that its therapies address real-world clinical challenges.
Travere conducts operations and clinical research across North America and Europe, leveraging strategic partnerships to facilitate market access and patient support programs. By combining scientific innovation with focused commercialization efforts, the company aims to deliver sustainable treatments that transform the standard of care for individuals living with rare kidney and metabolic disorders.
